Literature DB >> 6091268

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

H Mitsuya, M Popovic, R Yarchoan, S Matsushita, R C Gallo, S Broder.   

Abstract

A recently discovered member of the human T-cell leukemia virus (HTLV) family of retroviruses has been etiologically linked to the acquired immune deficiency syndrome (AIDS). This virus, which has been designated HTLV-III, is tropic for OKT4-bearing (helper-inducer) T cells. Moreover, the virus is cytopathic for these cells. Suramin is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it is known to inhibit the reverse transcriptase of a number of retroviruses. Suramin has now been found to block in vitro the infectivity and cytopathic effect of HTLV-III at doses that are clinically attainable in human beings.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6091268     DOI： 10.1126/science.6091268

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  69 in total

1.  Observations on the inhibition of HIV-1 reverse transcriptase by catechins.

Authors:  P S Moore; C Pizza
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.

Authors:  J Balzarini; D Schols; J Neyts; E Van Damme; W Peumans; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin.

Authors:  X J Yao; M A Wainberg; M Richard; M Pollak
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli.

Authors:  N Tanese; J Sodroski; W A Haseltine; S P Goff
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

Review 6.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

7.  [AIDS and HTLV-III in West Germany: the status February 1985].

Authors:  R Hehlmann; V Erfle; G Hunsmann; R Kurth
Journal:  Klin Wochenschr       Date:  1985-05-02

Review 8.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

9.  Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties.

Authors:  C Schiller; A Spittler; M Willheim; Z Szépfalusi; H Agis; M Köller; M Peterlik; G Boltz-Nitulescu
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 10.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.